1
|
Belchior ACG, de Freitas AM, Gusmao GS, dos Santos EJL, Lemos EF, Pompilio MA, Volpe-Chaves CE, de Brito EDCA, de Oliveira EF, Carreiro ACB, Paniago AMM. Clinical epidemiological and laboratory investigation in co-infection with COVID-19 and tuberculosis. Rev Inst Med Trop Sao Paulo 2024; 66:e65. [PMID: 39536219 PMCID: PMC11556834 DOI: 10.1590/s1678-9946202466065] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/12/2024] [Accepted: 09/25/2024] [Indexed: 11/16/2024] Open
Abstract
Currently, COVID-19 and tuberculosis (TB) are the deadliest infectious diseases worldwide. Their synergy, form of presentation, morbidity, and mortality are data that have been scarcely explored. Thus, this study aimed to characterize the clinical, epidemiological, and laboratory factors of this co-infection and to analyze the factors associated with the active TB among COVID-19 cases. A case-control study was conducted with a retrospective survey of 21 laboratory-confirmed COVID-19/TB co-infected patients (case group) and 21 COVID-19 patients (control group). The study included participants from eight hospitals in Campo Grande city, capital of Mato Grosso do Sul State, Brazil, from March 2020 to March 2022. Association analysis and binomial logistic regression were employed with statistical significance set at p≤0.05. From the 21 identified cases of COVID-19/TB co-infection, we found a more frequent association with HIV infection than the control-group, without worsening the outcome. COVID-19/TB patients had less dyspnea and less need for mechanical ventilation compared to the cases with COVID-19 only. On the other hand, COVID-19/TB patients had higher levels of C-reactive protein and lower hemoglobin levels, the latter variable was independently associated with COVID-19/TB. Among the clinical differences presented among COVID-19/TB co-infected patients, despite the association with HIV and lower clinical repercussions, only lower hemoglobin levels were associated with COVID-19/TB.
Collapse
Affiliation(s)
- Ana Carulina Guimarães Belchior
- Universidade Federal de Mato Grosso do Sul, Faculdade de Medicina, Programa de Pós-Graduação em Saúde e Desenvolvimento da Região Centro-Oeste, Campo Grande, Mato Grosso do Sul, Brazil
- Universidade Estadual de Mato Grosso do Sul, Faculdade de Medicina, Campo Grande, Mato Grosso do Sul, Brazil
- Hospital Regional de Mato Grosso do Sul, Campo Grande, Mato Grosso do Sul, Brazil
| | - Antônio Martins de Freitas
- Universidade Estadual de Mato Grosso do Sul, Faculdade de Medicina, Campo Grande, Mato Grosso do Sul, Brazil
| | - Grassyelly Silva Gusmao
- Unimed, Serviço de Controle de Infecção Hospitalar, Campo Grande, Mato Grosso do Sul, Brazil
| | - Evelin Jaqueline Lima dos Santos
- Universidade Federal de Mato Grosso do Sul, Hospital Universitário Maria Aparecida Pedrossian, Campo Grande, Mato Grosso do Sul, Brazil
| | - Everton Ferreira Lemos
- Universidade Estadual de Mato Grosso do Sul, Faculdade de Medicina, Campo Grande, Mato Grosso do Sul, Brazil
- Hospital CASSEMS, Núcleo de Ensino e Pesquisa, Campo Grande, Mato Grosso do Sul, Brazil
| | - Mauricio Antonio Pompilio
- Universidade Estadual de Mato Grosso do Sul, Faculdade de Medicina, Campo Grande, Mato Grosso do Sul, Brazil
| | - Cláudia Elizabeth Volpe-Chaves
- Hospital Regional de Mato Grosso do Sul, Campo Grande, Mato Grosso do Sul, Brazil
- Universidade Federal de Mato Grosso do Sul, Hospital Universitário Maria Aparecida Pedrossian, Campo Grande, Mato Grosso do Sul, Brazil
| | - Eliana da Costa Alvarenga de Brito
- Universidade Federal de Mato Grosso do Sul, Faculdade de Medicina, Programa de Pós-Graduação em Doenças Infecciosas e Parasitárias, Campo Grande, Mato Grosso do Sul, Brazil
| | - Everton Falcão de Oliveira
- Universidade Federal de Mato Grosso do Sul, Faculdade de Medicina, Programa de Pós-Graduação em Doenças Infecciosas e Parasitárias, Campo Grande, Mato Grosso do Sul, Brazil
| | | | - Anamaria Mello Miranda Paniago
- Universidade Federal de Mato Grosso do Sul, Faculdade de Medicina, Programa de Pós-Graduação em Saúde e Desenvolvimento da Região Centro-Oeste, Campo Grande, Mato Grosso do Sul, Brazil
- Universidade Federal de Mato Grosso do Sul, Faculdade de Medicina, Programa de Pós-Graduação em Doenças Infecciosas e Parasitárias, Campo Grande, Mato Grosso do Sul, Brazil
| |
Collapse
|
2
|
Darboe F, Reijneveld JF, Maison DP, Martinez L, Suliman S. Unmasking the hidden impact of viruses on tuberculosis risk. Trends Immunol 2024; 45:649-661. [PMID: 39181733 PMCID: PMC11769684 DOI: 10.1016/j.it.2024.07.008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/28/2024] [Revised: 07/25/2024] [Accepted: 07/25/2024] [Indexed: 08/27/2024]
Abstract
Tuberculosis (TB) is a leading cause of mortality from an infectious disease. In this opinion article, we focus on accumulating scientific evidence indicating that viral infections may contribute to TB progression, possibly allowing novel preventive interventions. Viruses can remodel the mammalian immune system, potentially modulating the risk of reactivating latent microbes such as Mycobacterium tuberculosis (Mtb). Evidence is mixed regarding the impact of emergent viruses such as SARS-CoV-2 on the risk of TB. Therefore, we posit that important knowledge gaps include elucidating which viral families increase TB risk and whether these provide unique or shared immune mechanisms. We also propose potential future research to define the contribution of viruses to TB pathogenesis.
Collapse
Affiliation(s)
- Fatoumatta Darboe
- Zuckerberg San Francisco General Hospital, Division of Experimental Medicine, University of California San Francisco, San Francisco, CA, USA
| | - Josephine F Reijneveld
- Zuckerberg San Francisco General Hospital, Division of Experimental Medicine, University of California San Francisco, San Francisco, CA, USA
| | - David P Maison
- Zuckerberg San Francisco General Hospital, Division of Experimental Medicine, University of California San Francisco, San Francisco, CA, USA
| | - Leonardo Martinez
- Boston University School of Public Health, Department of Epidemiology, Boston, MA, USA.
| | - Sara Suliman
- Zuckerberg San Francisco General Hospital, Division of Experimental Medicine, University of California San Francisco, San Francisco, CA, USA; Chan Zuckerberg Biohub, San Francisco, CA, USA.
| |
Collapse
|